Enry’s Island Unveils “Enry’s Island Adventures”: Venture Capital Becomes a Videogame and Launches the “Strap” Movement on Kickstarter
3.4.2026 10:47:00 EEST | Business Wire | Press release
Enry’s Island SpA (WBAG: EIOS), the world’s first publicly traded Venture Builder, today announced the upcoming Kickstarter launch of Enry’s Island Adventures (EIA), developed by its New York-based portfolio company, Enry’s Island Adventures LLC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402548535/en/
The game is designed to make venture capital accessible to new generations, transforming startup creation into an engaging and social gaming experience. After three years of R&D, EIA introduces a "bleisure" model (business + leisure): players learn to launch and manage startups through gameplay that includes real business KPIs, a customizable and evolving personal island, synchronous and asynchronous multiplayer modes, social events, and community-driven seasonal missions.
The “VC revolution”: teaching and democratizing through play
"I agree with Elon Musk that the best way to teach is through a video game, and this is even truer when it comes to teaching startups how to operate successfully and avoid common pitfalls," said Luigi Valerio Rinaldi, chairman of Enry’s Island.
Enry’s Island further maintains that "creativity and innovation always come from the peripheries of social systems," positioning EIA as a scalable method to bring best business development practices beyond traditional venture capital hubs.
From B2B to the "blue ocean" of micro-investors
Since its entry into the Vienna Stock Exchange in 2023, Enry’s Island has recorded a +132% share price growth and a +220% market cap growth over the last 18 months.
“We have consolidated our presence in the institutional B2B landscape, but the future is B2C,” said Alessandro Pacciana, board member of Enry’s Island and a 30-year veteran of international banking. “We see gamers as the venture capital protagonists of tomorrow. We are targeting that blue ocean of millions of micro-investors who can rewrite the rules of global finance.”
Why game dev studios join Enry’s Island
Enry’s Island invites game developers seeking more than just capital: they want true partnership, operational expertise, exit opportunities, and access to a cutting-edge ecosystem. The company confirmed it will invest over €5 million across 10 game development studios in 2026 and is now opening applications globally.
Expert insights: bridging the gap
"What stands out here is the alignment between capital and execution. In today’s market, funding alone is not enough; studios need structured support that spans product, market, and scalability. This model bridges that gap in a way that can create more predictable outcomes for both studios and investors," said Muhammad Hammad Arshad, venture partner and gaming specialist.
More than a game: the “startup lifestyle” and “strap”
EIA also aims to spark a cultural movement. Kickstarter backers will gain access to "out-of-the-box" rewards linked to the founder lifestyle, including exclusive sneakers and hoodies created in collaboration with top-tier designers, alongside the launch of "strap" (startup rap). This new musical genre, created with world-class producers, blends vaporwave, 80s retro vibes, and video game beats to tell the true story of building a company.
Campaign launch and participation
The Kickstarter campaign is set to launch in May 2026, managed from New York with an international reach. Game development studios and production houses can apply through the official channels on the Enry’s Island website to be considered for the 2026 portfolio and ecosystem.
For more information and to join the community:https://enrysisland.com/
About Enry’s Island SpA Enry’s Island is the world’s first publicly traded Venture Builder, headquartered in Italy with a global presence, supporting a portfolio of over 30 companies through a proprietary acceleration and funding framework. Enry’s Island Adventures LLC, based on Wall Street (New York), focuses on the convergence of gaming and finance to educate and inspire the next generation of global entrepreneurs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260402548535/en/
Contacts
Alessandro PaccianaHead of Investor Relations
alessandro.pacciana@enrysisland.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom